{"slideshow_credits": null, "snippet": "Inclusion on a federal list would mean Mylan could keep its list price high \u2014 or even raise it \u2014 without patients\u2019 complaining. But consumers would feel it indirectly....", "abstract": null, "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Eric", "role": "reported", "lastname": "LIPTON", "rank": 1, "organization": ""}, {"firstname": "Rachel", "role": "reported", "lastname": "ABRAMS", "rank": 2, "organization": ""}], "original": "By ERIC LIPTON and RACHEL ABRAMS", "contributor": ""}, "web_url": "http://www.nytimes.com/2016/09/16/business/epipen-maker-mylan-preventative-drug-campaign.html", "lead_paragraph": "Inclusion on a federal list would mean Mylan could keep its list price high \u2014 or even raise it \u2014 without patients\u2019 complaining. But consumers would feel it indirectly.", "headline": {"main": "EpiPen Maker Lobbies to Shift High Costs to Others", "print_headline": "Tactic by Maker of EpiPen Could Quell Protests"}, "_id": "57db9f9f95d0e021d7986943", "word_count": "2082", "multimedia": [{"height": 126, "url": "images/2016/09/16/business/16epipenlobby-1/16epipenlobby-1-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2016/09/16/business/16epipenlobby-1/16epipenlobby-1-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 391, "url": "images/2016/09/16/business/16epipenlobby-1/16epipenlobby-1-articleLarge.jpg", "legacy": {"xlarge": "images/2016/09/16/business/16epipenlobby-1/16epipenlobby-1-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "391"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2016/09/16/business/16epipenlobby-1/16epipenlobby-1-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/09/16/business/16epipenlobby-1/16epipenlobby-1-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2016-09-16T07:30:34+0000", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Mylan Inc", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Epinephrine (Drug)", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Lobbying and Lobbyists", "is_major": "N", "rank": "3"}, {"name": "subject", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Law and Legislation", "is_major": "N", "rank": "5"}, {"name": "subject", "value": "Health Insurance and Managed Care", "is_major": "Y", "rank": "6"}, {"name": "organizations", "value": "United States Preventive Services Task Force", "is_major": "N", "rank": "7"}], "blog": [], "subsection_name": null, "type_of_material": "News"}